Date of Abstract presentation11th December 2023IndicationsMultiple MyelomaAbstract Number1063Abstract typeOral
According to the findings presented at the ASH 2023, the CARTITUDE-4 trial included a cohort of 419 patients. As of the clinical cut-off, 99 patients in the CARVYKTI arm and 66 in the standard of care (SOC) arm underwent both baseline and 12-month patient-reported outcome (PRO) assessments, capturing data before disease progression. Initial PRO compliance stood at 100%, showing a gradual decline in subsequent visits to 74% in the CARVYKTI arm and 81% in the SOC arm at the 12-month milestone.
Throughout the analysis, patients in the CARVYKTI arm re...